CollPlant Biotechnologies (CLGN) Current Debt (2022)
CollPlant Biotechnologies' (CLGN) quarterly Current Debt came in at $50.2 million in Q4 2022, up 150.55% on a QoQ basis from $20.1 million in Q2 2022.
CollPlant Biotechnologies (CLGN) Current Debt (2022) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 1 years of Current Debt data on file, last reported at $50.2 million in Q4 2022.
- Quarterly Current Debt changed N/A year-over-year to $50.2 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $100.5 million (changed N/A YoY) and the FY2022 annual result came in at $50.2 million, changed N/A from the prior year.
- Current Debt climbed to $50.2 million in Q4 2022, from $20.1 million in the prior quarter.
- In the past five years, Current Debt ranged from a high of $50.2 million in Q4 2022 to a low of $20.1 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CollPlant Biotechnologies | 4.26 Mn | 4.26 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 50.24 Mn |
| Jun 30, 2022 | 20.05 Mn |
| Mar 31, 2022 | 30.19 Mn |